During 2010 third quarter, net sales grew 10% year-over-year. Omeprazole OTC and new product launches drove revenues in the U.S., but growth in Russia and India was a tad disappointing on the back of seasonality. Further, Europe de-grew on price erosion and declines in service segment revenue.
During the same quarter, net income surged 30% on lower tax rates, while operating profit margins (OPM) dipped. OPM declined 250 basis points quarter-over-quarter to 15.5% in the third quarter, led by higher sales and administrative expenses.The stock delivered 35% during the last one year, and other near-term triggers include launch of Fondaparinux and generic Allegra D-24 products in the U.S. The stock is trading at 16 times its estimated 2011 earnings.